The CEO of Cardiovascular Associates of America, and former CEO of the American College of Cardiology, shared his perspective on the rise of private equity investments in cardiology.
The document, which was designed to help guide both interventional cardiology trainees and program directors, was also endorsed by several other industry societies.
Some SGLT2 inhibitors have been linked to significant improvements in HF outcomes, but what about sotagliflozin? We spoke with Bertram Pitt, MD, to learn more.
The report, developed by Abbott, examined everything from AI to social determinants of health. One key finding was that patients grade their overall satisfaction with a physician or hospital based on much more than the effectiveness of their treatment.